RA Capital Healthcare Fund LP 4

What Happened

• Dr. Derek DiRocco, a Partner at RA Capital who serves on Mineralys Therapeutics’ board, was awarded a total of 14,500 restricted stock units (RSUs) on February 19, 2026. The filing shows two grants: 6,200 RSUs and 8,300 RSUs, each reported at $0.00 per share (no cash paid). These RSUs are contingent rights to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-02-19; filing date: 2026-02-20 (appears timely).
• Grants: 6,200 RSUs (direct) and 8,300 RSUs (derivative-style RSUs) — total 14,500 RSUs; price reported $0.00 per share.
• Vesting: Footnote states RSUs vest in one annual installment following the grant date.
• Ownership/beneficial interest: RSUs are held for the benefit of RA Capital funds (RA Capital Healthcare Fund and RA Capital Nexus III Fund). RA Capital and related entities disclaim beneficial ownership except for pecuniary interest; Dr. DiRocco must turn over net cash or stock received on settlement to the Adviser to offset advisory fees.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant.

Context

• RSU awards are compensation-type grants, not open-market purchases or sales, and do not by themselves indicate a buy/sell decision by the insider. Here, the awards are held for the benefit of institutional funds managed by RA Capital rather than being held personally by Dr. DiRocco. No immediate sale or exercise is reported.